The factors affecting the urinary excretion of oxalate are critical to the risk of forming calcium oxalate stones. This article reviews the role of dietary and intestinal oxalate in determining the level of oxalate excreted in urine. The amount of oxalate available for absorption throughout the intestine is highly dependent on the state of oxalate (a) in the food ingested, and (b) in the intestinal contents at each section of the intestinal tract since only the soluble form of oxalate can be absorbed. In this respect, the solubility of calcium oxalate (CaOx) under the prevailing conditions is paramount in determining the amount of oxalate available for absorption at any particular site. In turn, the main factors that control how much oxalate is in the soluble form are pH and the concentrations of calcium, magnesium and (indirectly) phosphate. Based on these parameters, a model of the intestine has been constructed which brings together the available evidence on the prevailing concentrations of these various factors at different sites in the intestine after allowing for dietary intake and the concentration of the above ions in intestinal secretions. The model then calculates the likely concentration of oxalate that is in the soluble form at each site and therefore available for passive absorption at that site. The model shows that oxalate is likely to be absorbed in the stomach, although it can be also absorbed in the small intestine, particularly at the distal end (after the absorption of calcium), and in the colon, since, on a normal intake of calcium and phosphate, most of the calcium in the large bowel would be anticipated to be precipitated as calcium phosphate under the prevailing alkaline conditions and high concentration of phosphate. The amount of free oxalate in the colon is also controlled by the presence or absence of Oxalobacter formigenes, an anaerobe that has an obligate requirement for oxalate as a source of energy and cellular carbon.

Keywords:
Intestinal absorption, Oxalate, Calcium, Magnesium, Fibre, pH, Urolithiasis
1.
Robertson WG, Peacock M, Heyburn PJ, Marshall DH, Clark PB: Risk factors in calcium stone disease of the urinary tract. Br J Urol 1978;50:449–454.
2.
Robertson WG, Peacock M: The cause of idiopathic calcium stone disease: Hypercalciuria or hyperoxaluria? Nephron 1980;26:105–110.
3.
Siener R, Ebert D, Nicolay C, Hesse A: Dietary risk factors for hyperoxaluria in calcium oxalate stone formers. Kidney Int 2003;63:1037–1043.
4.
Hodgkinson A: Oxalic Acid in Biology and Medicine. London, Academic Press, 1977.
5.
Zarembski PM, Hodgkinson A: The oxalic acid content of English diets. Br J Nutr 1962;16:627–634.
6.
Holmes RP, Kennedy M: Estimation of the oxalate content of foods and daily oxalate intake. Kidney Int 2000;57:1662–1667.
7.
Holmes RP, Goodman HO, Assimos DG: Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001;59:270–276.
8.
Massey LK: Dietary influences on urinary oxalate and risk of kidney stones. Front Biosci 2003;8:s584–s594.
9.
Marshall RW, Cochran M, Hodgkinson A: Relationship between calcium and oxalic acid intake in the diet and their excretion in the urine of normal and renal stone-forming subjects. Clin Sci 1972;43:91–99.
10.
Berg W, Bothor C, Pirlich W, Janitzky V: Influence of magnesium on the absorption and excretion of calcium and oxalate ions. Eur Urol 1986;12:274–282.
11.
Hanson CF, Frankos VH, Thompson WO: Bioavailability of oxalic acid from spinach, sugar beet fibre and a solution of sodium oxalate consumed by female volunteers. Food Chem Toxicol 1989;27:181–184.
12.
Hautmann RE: The stomach: A new and powerful oxalate absorption site in man. J Urol 1993;149:1401–1404.
13.
Hatch M, Freel RW, Vaziri ND: Mechanisms of oxalate absorption and secretion across the rabbit distal colon. Pflügers Arch 1994;426:101–109.
14.
Allison MJ, Dawson KA, Mayberry WR, Foss JG: Oxalobacter formigenes gen. nov., sp. nov.: Oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 1985;141:1–7.
15.
Allison MJ, Cook HM, Milne DB, Gallagher S, Clayman RV: Oxalate degradation by gastrointestinal bacteria from humans. J Nutr 1986;116:455–460.
16.
Robertson WG, Scurr DS: Prevention of ascorbic acid interference in the measurement of oxalic acid in urine by ion-chromatography. Clin Chim Acta 1984;140:97–99.
17.
Hughes H, Hagen L, Sutton RAL: Determination of urinary oxalate by high performance liquid chromatography. Anal Biochem 1982;119:1–3.
18.
Holmes RP, Goodman HO, Assimos DG: Dietary oxalate and its intestinal absorption. Scan Microsc 1995;9:1109–1118.
19.
Hesse A, Schneeberger W, Engfeld S, Von Unruh GE, Sauerbruch T: Intestinal hyperabsorption of oxalate in calcium oxalate stone formers: Application of a new test with [13C2] oxalate. J Am Soc Nephrol 1999;10(suppl 14):S329–S333.
20.
Hodgkinson A: Sampling errors in the determination of urine calcium and oxalate: Solubility of calcium oxalate in HCl-urine mixtures. Clin Chim Acta 1981;109:239–244.
21.
Robertson WG: Mild hyperoxaluria: A critical review and future outlook; in Borghi L, Meschi T, Briganti A, Schianchi T, Novarini A (eds): Kidney Stones. Cosenza, Editoriale Bios, 1999, pp 33–42.
22.
Robertson WG, Nordin BEC: Activity products in urine; in Hodgkinson A, Nordin BEC (eds): Proceedings of the Renal Stone Research Symposium. London, Churchill, 1969, pp 221–232.
23.
Hallson PC, Rose GA: Chemical measurement of calcium oxalate crystalluria: Results in various causes of calcium urolithiasis. Urol Int 1990;45:332–335.
24.
Lemann J, Pleuss JA, Worcester EM, Hornick L, Schrab D, Hoffmann RG: Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults. Kidney Int 1996;49:200–208.
25.
Leonetti F, Dussol B, Berthezene P, Thirion X, Berland Y: Dietary and urinary risk factors for stones in idiopathic calcium stone formers compared with healthy subjects. Nephrol Dial Transplant 1998;13:617–622.
26.
Neuhaus TJ, Belzer T, Blau N, Hoppe B, Sidhu H, Leumann E: Urinary oxalate excretion in urolithiasis and nephrocalcinosis. Arch Dis Child 2000;82:322–326.
27.
Brzezinski E, Durning AM, Grasse B, Fusselman, Ciaraldi T: Oxalate Content of Selected Foods. San Diego, University of California at San Diego, 1998.
28.
Terris MK, Issa MM, Tacker JR: Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57:26–29.
29.
Harris KS, Richardson KE: Glycolate in the diet and its conversion to urinary oxalate in the rat. Invest Urol 1980;18:106–109.
30.
Robertson WG, Heyburn PJ, Peacock M, Hanes F, Swaminathan R: The effect of a high animal protein intake on the risk of calcium stone-formation in the urinary tract. Clin Sci 1979;57:285–288.
31.
Nguyen Q-V, Kälin A, Drouve U, Casez J-P, Jaeger Ph: Sensitivity to meat protein intake and hyperoxaluria in idiopathic calcium stone-formers. Kidney Int 2001;59:2273–2281.
32.
Marangella M, Bianco O, Martini C, Petrarulo M, Vitale C, Linari F: Effect of animal and vegetable protein on oxalate excretion in idiopathic calcium stone disease. Br J Urol 1989;63:348–351.
33.
Urivetsky M, Kessaris D, Smith AD: Ascorbic acid overdosing: A risk factor for calcium oxalate nephrolithiasis. J Urol 1992;147:1215–1218.
34.
Auer BL, Auer D, Rodgers AL: Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C. Eur J Clin Invest 1998;28:695–700.
35.
Traxer O, Huet B, Poindexter J, Pak CYC, Pearle MS: Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 2003;170:397–401.
36.
Curhan GC, Willett WC, Rimm EB, Stampfer MJ: A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol 1996;155:1847–1851.
37.
Gerster H: No contribution of ascorbic acid to renal calcium oxalate stones. Ann Nutr Metab 1997;41:269–282.
38.
Mazzachi BC, Teubner JK, Ryall RL: The effect of ascorbic acid on urine oxalate measurement; in Schwille PO, Smith JH, Robertson WG, Vahlensieck W (eds): Urolithiasis and Related Clinical Research. New York, Plenum Press, 1985, pp 649–652.
39.
Hatch M, Freel RW: Alterations in intestinal transport of oxalate in disease states. Scan Microsc 1995;9:1121–1126.
40.
Chen Z, Ye Z, Zeng L, Yang W: Clinical investigation on gastric oxalate absorption. Chin Med J (Engl) 2003;116:1749–1751.
41.
Liebman M, Costa G: Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads. J Urol 2000;163:1565–1569.
42.
Diamond KL, Fox CC, Barch DH: Role of cecal pH in intestinal oxalate absorption in the rat. J Lab Clin Med 1988;112:352–356.
43.
Siener R, Glatz S, Nicolay C, Hesse A: The role of overweight and obesity in calcium oxalate stone formation. Obes Res 2004;12:106–113.
44.
Brinkley L, McGuire J, Gregory J, Pak CYC: Bioavailability of oxalate in foods. Urology 1981;17:534–538.
45.
Hossain RZ, Ogawa Y, Morozumi M, Sugaya K, Hatano T: Urinary oxalic acid differs after oral loading of rats with various oxalate salts. Int J Urol 2003;10:43–48.
46.
Savage GP, Charrier MJ, Vanhanen L: Bioavailability of soluble oxalate from tea and the effect of consuming milk with the tea. Eur J Clin Nutr 2003;57:415–419.
47.
Brogren M, Savage GP: Bioavailability of soluble oxalate from spinach eaten with an without milk products. Asia Pac J Nutr 2003;12:219–224.
48.
Gleeson MJ, Thompson AS, Mehta S, Griffith DP: Effect of unprocessed wheat bran on calciuria and oxaluria in patients with urolithiasis. Urology 1990;35:231–234.
49.
Jahnen A, Heynck H, Gertz B, Classen A, Hesse A: Dietary fibre: The effectiveness of a high bran intake in reducing renal calcium excretion. Urol Res 1992;20:3–6.
50.
Robertson WG, Hughes H, Husain I, Al-Faqih S, Arafat A, Chakrabarti A, Shamsuddin A, Tipton L: Simultaneous treatment of calcium oxalate and uric acid stone disease in Saudi Arabia; in Ryall R, Bais R, Marshall VR, Rofe AM, Smith LH, Walker VR (eds): Urolithiasis 2. New York, Plenum Press, 1994, pp 581–586.
51.
Hess B, Jost C, Zipperle L, Takkinen R, Jaeger Ph: High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 1998;13:2241–2247.
52.
Siener R, Jahnen A, Hesse A: Influence of a mineral water rich in calcium, magnesium and bicarbonate on urine composition and the risk of calcium oxalate crystallization. Eur J Clin Nutr 2004;58:270–276.
53.
Erickson SB, Cooper K, Broadus AE, Smith LH, Werness PG, Binder HJ, Dobbins JW: Oxalate absorption and postprandial urine supersaturation in an experimental human model of absorptive hypercalciuria. Clin Sci 1984;67:131–138.
54.
Robertson WG, Hughes H: Importance of mild hyperoxaluria in the pathogenesis of urolithiasis: New evidence from studies in the Arabian Peninsula. Scanning Microsc 1993;7:391–402.
55.
Baetz AL, Allison MJ: Purification and characterization of oxalyl-coenzyme A decarboxylase fro Oxalobacter formigenes. J Bacteriol 1989;171:2605–2608.
56.
Stewart CS, Duncan SH, Cave DR: Oxalobacter formigenes and its role in oxalate metabolism in the human gut. FEMS Microbiol Lett 2004;230:1–7.
57.
Kwak C, Kim HK, Kim EC, Choi MS, Kim HH: Urinary oxalate levels and the enteric bacterium Oxalobacter formigenes in patients with calcium oxalate urolithiasis. Eur Urol 2003;44:475–481.
58.
Kumar R, Mukherjee M, Bhandari M, Kumar A, Sidhu H, Mittal RD: Role of Oxalobacter formigenes in calcium oxalate stone disease: A study from North India. Eur Urol 2002;41:318–322.
59.
Troxel SA, Sidhu H, Kaul P, Low RK: Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate. J Endourol 2003;17:173–176.
60.
Mikami K, Akakura K, Takei K, Ueda T, Mizoguchi K, Noda M, Miyake M, Ito H: Association of absence of intestinal oxalate degrading bacteria with urinary calcium oxalate stone formation. Int J Urol 2003;10:293–296.
61.
Siener R, Ebert D, Hesse A: Urinary oxalate excretion in female calcium oxalate stone formers with and without a history of recurrent urinary tract infections. Urol Res 2001;29:245–248.
62.
Robertson WG, Whitfield HN, Unwin RJ, Mansell MA, Neild GH: The changing pattern of urinary stone disease in the UK and its causes. Br J Urol Int 2000;85(suppl 5):37–38.
63.
Sidhu H, Hoppe B, Hesse A, Tenbrock K, Bromme S, Rietschel E, Peck AB: Absence of Oxalobacter formigenes in cystic fibrosis patients: A risk factor for hyperoxaluria. Lancet 1998;352:1026–1029.
64.
Sidhu H, Schmidt ME, Cornelius, Thamiselvan S, Khan SR, Hesse A, Peck AB: Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: Possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 1999;10(suppl 14):S334–S340.
65.
Campieri C, Campieri M, Bertuzzi V, Swennen E, Matteuzzi D, Stefoni S, Pirovano F, Centi C, Ulisse S, Famularo G, De Simone C: Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int 2001;60:1097–1105.
66.
Hokama S, Honma Y, Toma C, Ogawa Y: Oxalate-degrading Enterococcus faecalis. Microbiol Immunol 2000;44:235–240.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.